The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


UNIPHYLLIN Continus 400 mg Prolonged-Release Tablets

400 milligram(s) Prolonged-release tablet

Mundipharma Pharmaceuticals LimitedPA1688/011/003

Main Information

Trade NameUNIPHYLLIN Continus 400 mg Prolonged-Release Tablets
Active SubstancesTheophylline
Strength400 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderMundipharma Pharmaceuticals Limited
Licence NumberPA1688/011/003

Group Information

ATC CodeR03DA Xanthines
R03DA04 theophylline

Status

Authorised/WithdrawnAuthorised
Licence Issued20/06/1983
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back